Specialty Pharmaceuticals Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 11.74 Billion |
| Market Size (2029) | USD 55.61 Billion |
| CAGR (2024 - 2029) | 36.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Specialty Pharmaceuticals Market Analysis
The Specialty Pharmaceuticals Market size is estimated at USD 11.74 billion in 2024, and is expected to reach USD 55.61 billion by 2029, growing at a CAGR of 36.5% during the forecast period (2024-2029).
The market studied is experiencing significant growth driven by several key factors. The increasing prevalence of chronic and rare diseases, coupled with robust research and development activities, are creating a strong demand for new treatments. This demand is further amplified by the launch of new drugs, regulatory approvals, and strategic initiatives undertaken by major market players.
The growing burden of chronic diseases is expected to increase the utilization of specialty pharmaceuticals, thereby boosting the growth of the market over the forecast period. For instance, according to the American Cancer Society, an estimated 2.0 million new cancer cases will be diagnosed in 2024, among which prostate cancer is estimated to be 288,300, followed by 238.340 cases of lung cancer and 300,590 cases of female breast cancer.
Furthermore, as per Canadian government statistics released in May 2022, approximately 233,900 Canadians were diagnosed with cancer in 2022, with prostate cancer projected to continue as the most prevalent type of cancer. Similarly, the growing burden of chronic and rare diseases is anticipated to drive market growth in the coming years. This is underscored by statistics from the Genetic and Rare Diseases (GARD) Information Centre, which revealed that in May 2022, 1 in 10 Americans (approximately 30 million people) lived with a rare disease, with an estimated 7,000 different rare diseases identified.
Further, growing research and development activities by pharmaceutical firms are expected to boost the market over the forecast period. For instance, in March 2023, Eisai Co. Ltd and Biogen Inc. revealed that the FDA had accepted Eisai's supplemental Biologics Licence Application (sBLA) for LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use, paving the way for LEQEMBI's accelerated approval to be converted to a traditional approval. Similarly, in March 2022, Mankind Pharma Ltd announced an investment in Actimed Therapeutics Ltd, a UK-based clinical-stage specialty pharmaceutical company. Actimed is dedicated to developing innovative treatments for cancer cachexia, a critical unmet need in cancer care, as well as other muscle-wasting disorders.
Moreover, the launch of new specialty pharmacies will also drive market growth. For instance, in March 2022, Boston Children's Hospital partnered with Shields Health Solutions to launch Boston Children's Pharmacy, a specialty pharmacy, to help young patients and their families get better access to specialized pharmacy services, including help with prior authorizations and specialized medication. Such launches of pharmacies will make specialized pharmaceuticals more accessible to people in the country, thereby contributing to the overall market's growth.
Therefore, owing to the abovementioned factors, the market studied is expected to grow significantly during the forecast period. However, the high costs of specialty medications are expected to hinder market growth during the forecast period.
Specialty Pharmaceuticals Market Trends
Oncology Segment Expected to Account for a Significant Market Share Over the Forecast Period
Oncology is a branch of medicine that deals with cancer prevention, diagnosis, and treatment. The rising incidences of cancer worldwide, increasing product approvals, a rise in research and development studies, and increasing strategic initiatives by key market players are expected to further drive the market's growth. For instance, according to data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2023, an estimated 279,260 new cases of cancer were expected to occur in Spain by the end of 2023, out of which 42,721 new cases of colorectal cancer, 31,282 cases of lung cancer, and 21,694 cases of urinary bladder cancer were expected to occur in Spain. Thus, the high burden of cancer is expected to contribute to the segment’s growth over the forecast period.
The product approvals expand the company's product offerings and geographical footprint, contributing to market growth. For instance, in March 2022, Accord BioPharma, the United States’ Specialty division of Intas Pharmaceuticals Ltd, launched the CAMCEVI (leuprolide) 42 mg injection emulsion to treat advanced prostate cancer in adults in the United States. Additionally, in January 2022, ALX Oncology Holdings Inc. received an orphan drug designation from the US Food and Drug Administration (FDA) for Evorpacept, a next-generation CD47 blocker, to treat patients with gastric cancer and gastroesophageal junction cancer.
Furthermore, in February 2022, Humana Specialty Pharmacy added two drugs to its comprehensive, personalized, and targeted oncology therapies: TAGRISSO (osimertinib), a drug that helps certain patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) manage their disease, and LENVIMA (lenvatinib), a drug that helps patients with different forms of cancer, including certain types of thyroid, liver, and kidney cancers. Such additions help expand the product portfolio, thereby driving the market.
Thus, due to the factors mentioned above, the segment studied is expected to contribute to the significant growth of the market.
North America Expected to Hold a Significant Market Share With its Dominance Expected to Continue Over the Forecast Period
The primary driving factors for the growth of the North American specialty pharmaceuticals market are the increasing prevalence of chronic and rare diseases such as sickle cell disease, cancer, and HIV, increasing product launches, rising strategic initiatives by key market players, and increasing research and development activities.
The rising burden of chronic diseases is expected to boost the market over the forecast period. For instance, as estimated in the American Heart Association 2022 Journal, by 2035, more than 130 million adults in the United States will have heart disease. Similarly, according to the CDC, in July 2022, 12.1 million Americans were expected to have atrial fibrillation (AFib) by 2030. Furthermore, as per the Canadian Cancer Statistics 2023 report, about 239.2 thousand new cancer cases were reported in 2023 in Canada, compared to 233.9 thousand in 2022. Thus, the growing burden of cancer is expected to generate demand for drug research and manufacturing services, which is likely to contribute to the segment’s growth. Thus, the huge burden of cancer is expected to increase demand for specialty pharmaceuticals, boosting market growth.
Moreover, strategic initiatives taken by key market players, such as product launches, partnerships, new programs, mergers, and acquisitions, will drive market growth. For instance, in February 2022, the US Food and Drug Administration granted orphan drug designation to CT103A, a chimeric antigen receptor T-cell therapy in development for adults with relapsed or refractory multiple myeloma.
Rising investments will also boost innovation in the market studied, thereby driving it. For instance, in April 2022, Free Market Health secured USD 13.5 million in Series A financing led by Alta Partners with participation from existing investors Highmark Ventures and 653 Investment Partners. This investment will help the company scale its innovative, care-driven marketplace platform that streamlines the complex and opaque specialty medication fulfillment process to benefit specialty pharmacies and payers. Therefore, investments will expand the company’s product offerings and geographical reach, thus driving the market studied.
Therefore, the abovementioned developments are expected to result in the North American market registering lucrative growth.
Specialty Pharmaceuticals Industry Overview
The specialty pharmaceuticals market is fragmented. The market studied is boosted by strategic initiatives such as mergers, acquisitions, and partnerships adopted by key market players. The major players in the market studied include Teva Pharmaceuticals Industries Ltd, AbbVie Inc., Amgen Inc., Johnson and Johnson, and Bristol Myers Squibb.
Specialty Pharmaceuticals Market Leaders
-
Teva Pharmaceutical Industries Ltd.
-
AbbVie, Inc.
-
Amgen Inc.
-
Johnson and Johnson
-
Bristol-Myers Squibb Company
*Disclaimer: Major Players sorted in no particular order
Specialty Pharmaceuticals Market News
- June 2024: Prime Therapeutics and Magellan Rx Management introduced a novel approach for locating pharmacies that dispense specialty drugs. Termed Pharmacy Match, this solution not only features an extended specialty pharmacy network but also enables real-time cost comparisons for drugs within the network.
- January 2023: TG Therapeutics Inc. reported the commercial launch of BRIUMVI (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS) while including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Specialty Pharmaceuticals Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Chronic and Rare Diseases
4.2.2 Growing Research and Development Activities
4.3 Market Restraints
4.3.1 High Cost of Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD)
5.1 By Therapeutic Area
5.1.1 Oncology
5.1.2 Inflammatory Conditions
5.1.3 Multiple Sclerosis
5.1.4 Infectious Diseases
5.1.5 Other Therapeutic Areas (Women's Health and Respiratory)
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Transdermal
5.3 By Distribution Channel
5.3.1 Hospitals
5.3.2 Retail Pharmacies
5.3.3 Other Distribution Channels
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceutical Industries Ltd
6.1.2 AbbVie Inc.
6.1.3 Amgen Inc.
6.1.4 Johnson and Johnson
6.1.5 Bristol-Myers Squibb Company
6.1.6 Merck & Co. Inc.
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Gilead Sciences Inc.
6.1.9 Novartis AG
6.1.10 Sanofi
6.1.11 Pfizer
6.1.12 Viatris
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Specialty Pharmaceuticals Industry Segmentation
As per the scope of the report, specialty pharmaceuticals are branded injectables, infusions, or oral medications with high cost and high complexity, with limited or exclusive availability and distribution, that are used to treat chronic or rare diseases.
The specialty pharmaceuticals market is segmented by therapeutic area, route of administration, distribution channel, and geography. By therapeutic area, the market is segmented into oncology, inflammatory conditions, multiple sclerosis, infectious diseases, and other therapeutic areas. By route of administration, the market is segmented into oral, parenteral, and transdermal. By distribution channel, the market is segmented into hospitals, retail pharmacies, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.
| By Therapeutic Area | |
| Oncology | |
| Inflammatory Conditions | |
| Multiple Sclerosis | |
| Infectious Diseases | |
| Other Therapeutic Areas (Women's Health and Respiratory) |
| By Route of Administration | |
| Oral | |
| Parenteral | |
| Transdermal |
| By Distribution Channel | |
| Hospitals | |
| Retail Pharmacies | |
| Other Distribution Channels |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Specialty Pharmaceuticals Market Research Faqs
How big is the Specialty Pharmaceuticals Market?
The Specialty Pharmaceuticals Market size is expected to reach USD 11.74 billion in 2024 and grow at a CAGR of 36.5% to reach USD 55.61 billion by 2029.
What is the current Specialty Pharmaceuticals Market size?
In 2024, the Specialty Pharmaceuticals Market size is expected to reach USD 11.74 billion.
Who are the key players in Specialty Pharmaceuticals Market?
Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Amgen Inc., Johnson and Johnson and Bristol-Myers Squibb Company are the major companies operating in the Specialty Pharmaceuticals Market.
Which is the fastest growing region in Specialty Pharmaceuticals Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Specialty Pharmaceuticals Market?
In 2024, the North America accounts for the largest market share in Specialty Pharmaceuticals Market.
What years does this Specialty Pharmaceuticals Market cover, and what was the market size in 2023?
In 2023, the Specialty Pharmaceuticals Market size was estimated at USD 7.45 billion. The report covers the Specialty Pharmaceuticals Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Specialty Pharmaceuticals Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the major factors driving the Global Specialty Pharmaceuticals Market?
The major factors driving the Global Specialty Pharmaceuticals Market are a) Increased focus on personalized medicine and targeted therapies b) Growing research and development activities
Specialty Pharmaceuticals Industry Report
The global specialty pharmaceuticals market is poised for significant growth, propelled by robust R&D backed by significant government healthcare investments. Segmented by application, the oncology segment notably stands out due to its pivotal role in cancer therapy, including treatments such as chemotherapy and targeted therapy. Distribution is handled through both offline and online channels, with offline playing a key role in ensuring patient access to medications and providing tailored healthcare guidance. Regionally, North America dominates due to substantial cancer research investments and a high incidence of chronic diseases. Advanced technology and strong healthcare infrastructure also bolster this region's market dominance. However, the industry faces challenges such as rising labor costs and volatile raw material prices which could impede growth. Nonetheless, an aging population and the escalating burden of chronic diseases are expected to spike demand for specialty pharmaceutical products. The market is also evolving with significant technological innovations and a shift towards enhanced vendor engagement via social media, making these pharmaceuticals more accessible. For comprehensive insights and future market outlook, get a sample of this industry analysis as a free report PDF download.
Specialty Pharmaceuticals Market Report Snapshots
